Overview
Charles River Laboratories International, Inc., headquartered in Wilmington, Massachusetts, USA, is a prominent global company specialized in a variety of preclinical and clinical laboratory services for the pharmaceutical, medical device, and biotechnology industries. It facilitates drug discovery and development primarily by providing research models and associated services, and preclinical and clinical support to its partners. The company plays a pivotal role in pharmacology research, offering in vivo and in vitro testing, including safety assessments, biological assay development, and genetic testing. Through strategic acquisitions and global expansion, Charles River has broadened its capabilities and enhanced its position in the competitive contract research organization (CRO) market, supporting clients from early-stage drug discovery through to final product launch.
Basic Stats
The share price of Charles River Laboratories International, Inc. as of September 5, 2025 is $163.99 / share. This is an increase of 0.42% from the prior week. The market cap (or net worth) of Charles River Laboratories International, Inc. as of September 5, 2025 is $8,069.78 MM.
The Factor Analysis chart (below right) shows a view of Charles River Laboratories International, Inc. from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 8,069.78 MM |
| EV | 10,265.70 MM |
| Shares Out. | 49.21 MM |
| Earnings Date | |
| EPS (TTM) | -1.36 |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | 0.41 |
| Short Shares Avail. | 1.40 MM |
| Short Interest | 3.02 MM |
| Short Float | 6.20 % |
| Days to Cover | 6.31 days |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | -14.23 % |
| Volatility (1 yr) | 0.54 |
| Beta | 0.94 |
| Sharpe Ratio (1 yr) | -0.34 |
| Sortino Ratio (1 yr) | -0.51 |
| PE Ratio | -120.37 |
| Price/Book | 2.37 |
| Price/TBV | -43.53 |
| Book/Market | 0.42 |
| EBIT/EV | -0.00 |
| EBIT(3yr avg)/EV | 0.04 |
| ROA | -0.01 |
| ROE | -0.02 |
| ROIC | -0.01 |
| CROIC | 0.00 |
| OCROIC | 0.13 |
| Implied Volatility | 35.45 % |
| Put/Call OI Ratio | 0.63 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Charles River Laboratories International, Inc. is $176.64. The forecasts range from a low of $143.42 to a high of $210.00. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Charles River Laboratories International, Inc.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2023-01-12 | Jefferies | Buy | Hold | Downgrade |
| 2023-01-11 | Baird | Outperform | Maintains | |
| 2023-02-23 | Credit Suisse | Outperform | Maintains | |
| 2023-02-23 | Morgan Stanley | Equal-Weight | Maintains | |
| 2023-02-23 | Citigroup | Buy | Maintains | |
| 2023-02-23 | Guggenheim | Neutral | Buy | Upgrade |
| 2022-11-03 | Morgan Stanley | Equal-Weight | Maintains | |
| 2022-11-03 | JP Morgan | Overweight | Maintains | |
| 2022-11-03 | Credit Suisse | Outperform | Maintains | |
| 2022-09-30 | Jefferies | Hold | Buy | Upgrade |
| 2022-08-25 | Credit Suisse | Outperform | Initiate | |
| 2022-08-16 | Wells Fargo | Overweight | Maintains | |
| 2022-08-04 | Morgan Stanley | Overweight | Equal-Weight | Downgrade |
| 2022-07-14 | Deutsche Bank | Buy | Maintains | |
| 2022-05-24 | Guggenheim | Neutral | Initiate | |
| 2022-05-05 | Morgan Stanley | Overweight | Maintains | |
| 2022-05-05 | Keybanc | Overweight | Maintains | |
| 2022-04-25 | Wells Fargo | Overweight | Maintains | |
| 2022-04-25 | Jefferies | Buy | Hold | Downgrade |
| 2022-04-07 | Stephens & Co. | Overweight | Initiate | |
| 2022-02-17 | Morgan Stanley | Overweight | Maintains | |
| 2022-02-17 | Keybanc | Overweight | Maintains | |
| 2022-02-17 | Citigroup | Neutral | Buy | Upgrade |
| 2021-11-04 | Morgan Stanley | Overweight | Maintains | |
| 2021-08-17 | UBS | Buy | Maintains | |
| 2021-07-20 | Credit Suisse | Neutral | Maintains | |
| 2021-05-28 | JP Morgan | Overweight | Maintains | |
| 2021-05-28 | Credit Suisse | Neutral | Maintains | |
| 2021-05-28 | Citigroup | Neutral | Maintains | |
| 2021-05-25 | Truist Securities | Buy | Maintains | |
| 2021-05-14 | Keybanc | Overweight | Maintains | |
| 2021-02-22 | Morgan Stanley | Overweight | Maintains | |
| 2021-02-19 | Morgan Stanley | Overweight | Maintains | |
| 2021-02-18 | Truist Securities | Buy | Maintains | |
| 2021-02-18 | Deutsche Bank | Buy | Maintains | |
| 2020-12-16 | Citigroup | Buy | Neutral | Downgrade |
| 2020-11-24 | KeyBanc | Overweight | Maintains | |
| 2020-10-30 | Morgan Stanley | Overweight | Maintains | |
| 2020-09-14 | Argus Research | Buy | Maintains | |
| 2020-09-10 | Jefferies | Hold | Buy | Upgrade |
| 2020-08-18 | KeyBanc | Overweight | Maintains | |
| 2020-08-06 | Morgan Stanley | Overweight | Maintains | |
| 2020-08-06 | Citigroup | Buy | Maintains | |
| 2020-07-01 | B of A Securities | Neutral | Buy | Upgrade |
| 2020-05-13 | UBS | Neutral | Buy | Upgrade |
| 2020-05-12 | Deutsche Bank | Buy | Maintains | |
| 2020-05-08 | SunTrust Robinson Humphrey | Buy | Maintains | |
| 2020-05-08 | Morgan Stanley | Overweight | Maintains | |
| 2020-05-08 | JP Morgan | Overweight | Maintains | |
| 2020-05-08 | Credit Suisse | Neutral | Maintains | |
| 2020-05-08 | Citigroup | Buy | Maintains | |
| 2020-04-21 | Jefferies | Buy | Hold | Downgrade |
| 2020-04-09 | Citigroup | Buy | Maintains | |
| 2020-04-06 | SunTrust Robinson Humphrey | Buy | Maintains | |
| 2020-03-30 | Wells Fargo | Overweight | Maintains | |
| 2020-03-27 | Morgan Stanley | Equal-Weight | Overweight | Upgrade |
| 2020-03-26 | Barclays | Equal-Weight | Maintains | |
| 2020-03-23 | Jefferies | Buy | Maintains | |
| 2020-03-17 | SunTrust Robinson Humphrey | Buy | Maintains | |
| 2020-03-02 | Deutsche Bank | Buy | Initiate | |
| 2020-02-18 | Wolfe Research | Peer Perform | Outperform | Upgrade |
| 2020-02-12 | Morgan Stanley | Equal-Weight | Maintains | |
| 2020-02-12 | Baird | Outperform | Maintains | |
| 2020-02-11 | CFRA | Strong Buy | Maintains | |
| 2020-01-10 | Goldman Sachs | Neutral | Buy | Upgrade |
| 2020-01-08 | Wells Fargo | Overweight | Initiate | |
| 2020-01-07 | Citigroup | Buy | Initiate | |
| 2019-12-17 | Baird | Outperform | Maintains | |
| 2019-12-09 | KeyBanc | Overweight | Maintains | |
| 2019-11-07 | UBS | Neutral | Maintains | |
| 2019-10-18 | Bank of America | Buy | Neutral | Downgrade |
| 2019-09-16 | SunTrust Robinson Humphrey | Buy | Maintains | |
| 2019-03-18 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2019-03-11 | KeyBanc | Overweight | Overweight | Maintains |
| 2018-12-03 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2018-11-08 | RBC Capital | Outperform | Outperform | Maintains |
| 2018-11-08 | Raymond James | Outperform | Outperform | Maintains |
| 2018-11-08 | Baird | Outperform | Outperform | Maintains |
| 2018-09-25 | Credit Suisse | Neutral | Neutral | Maintains |
| 2018-09-17 | Baird | Outperform | Outperform | Maintains |
| 2018-09-11 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2018-08-27 | Argus | Buy | Buy | Maintains |
| 2018-08-23 | Raymond James | Market Perform | Outperform | Upgrade |
| 2018-08-21 | Credit Suisse | Neutral | Neutral | Maintains |
| 2018-08-09 | Jefferies | Buy | Buy | Maintains |
| 2018-08-09 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2018-07-17 | RBC Capital | Sector Perform | Outperform | Upgrade |
| 2018-07-16 | Bank of America | Buy | Buy | Maintains |
| 2018-06-15 | KeyBanc | Sector Weight | Overweight | Upgrade |
| 2018-04-20 | Mitsubishi UFJ | Neutral | Initiate | |
| 2018-03-14 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2018-02-14 | SunTrust Robinson Humphrey | Hold | Buy | Upgrade |
| 2018-02-14 | JP Morgan | Overweight | Overweight | Maintains |
| 2018-01-22 | SunTrust Robinson Humphrey | Buy | Hold | Downgrade |
| 2018-01-19 | Evercore ISI Group | In-Line | Initiate | |
| 2017-12-13 | Argus | Buy | Initiate | |
| 2017-11-13 | Jefferies | Buy | Maintains | |
| 2017-11-10 | Bank of America | Buy | Maintains | |
| 2017-10-09 | Jefferies | Buy | Maintains | |
| 2017-09-19 | RBC Capital | Sector Perform | Initiate | |
| 2017-01-04 | Evercore ISI Group | Hold | Buy | Upgrade |
| 2016-12-16 | Goldman Sachs | Sell | Neutral | Upgrade |
| 2016-11-30 | Barclays | Underweight | Equal-Weight | Upgrade |
| 2016-09-06 | UBS | Neutral | Sell | Downgrade |
| 2016-08-04 | Jefferies | Buy | Maintains | |
| 2016-08-04 | Citigroup | Neutral | Maintains | |
| 2016-06-21 | Credit Suisse | Neutral | Initiate | |
| 2016-05-20 | Barclays | Underweight | Maintains | |
| 2016-04-26 | Gabelli & Co. | Buy | Initiate | |
| 2016-02-11 | UBS | Neutral | Maintains | |
| 2016-02-11 | Deutsche Bank | Hold | Maintains | |
| 2016-01-08 | Jefferies | Buy | Maintains | |
| 2016-01-08 | Baird | Outperform | Maintains | |
| 2016-01-07 | Wells Fargo | Market Perform | Outperform | Downgrade |
| 2015-11-05 | Deutsche Bank | Hold | Maintains | |
| 2015-10-12 | Wells Fargo | Underperform | Market Perform | Upgrade |
| 2015-07-31 | Citigroup | Neutral | Maintains | |
| 2015-07-10 | Morgan Stanley | Equal-Weight | Maintains | |
| 2015-07-10 | Barclays | Equal-Weight | Underweight | Downgrade |
| 2015-07-10 | Bank of America | Neutral | Buy | Upgrade |
| 2015-05-04 | Edward Jones | Neutral | Buy | Upgrade |
| 2015-04-24 | Jefferies | Buy | Maintains | |
| 2015-04-24 | Barclays | Equal-Weight | Maintains | |
| 2015-04-07 | Wells Fargo | Market Perform | Underperform | Downgrade |
| 2015-03-26 | SunTrust Robinson Humphrey | Buy | Neutral | Downgrade |
| 2015-02-12 | Jefferies | Buy | Maintains | |
| 2015-02-12 | Deutsche Bank | Hold | Maintains | |
| 2015-01-28 | Jefferies | Buy | Maintains | |
| 2015-01-23 | William Blair | Market Perform | Outperform | Upgrade |
| 2015-01-16 | Jefferies | Buy | Maintains | |
| 2014-11-05 | Credit Suisse | Neutral | Maintains | |
| 2014-11-03 | Citigroup | Neutral | Maintains | |
| 2014-10-31 | Deutsche Bank | Hold | Maintains | |
| 2014-10-30 | Jefferies | Buy | Maintains | |
| 2014-10-15 | SunTrust Robinson Humphrey | Neutral | Buy | Upgrade |
| 2014-08-13 | Deutsche Bank | Hold | Maintains | |
| 2014-08-08 | JP Morgan | Overweight | Maintains | |
| 2014-08-08 | Credit Suisse | Neutral | Maintains | |
| 2014-06-24 | SunTrust Robinson Humphrey | Neutral | Initiate | |
| 2014-05-02 | Citigroup | Hold | Maintains | |
| 2014-03-19 | KeyBanc | Hold | Initiate | |
| 2014-02-18 | Citigroup | Neutral | Initiate | |
| 2013-12-12 | Bank of America | Neutral | Maintains | |
| 2013-12-11 | Raymond James | Underperform | Market Perform | Upgrade |
| 2013-11-20 | Deutsche Bank | Hold | Initiate | |
| 2013-10-01 | Cantor Fitzgerald | Buy | Initiate | |
| 2013-09-24 | Credit Suisse | Neutral | Initiate | |
| 2013-09-17 | UBS | Neutral | Initiate | |
| 2013-06-18 | Goldman Sachs | Neutral | Sell | Downgrade |
| 2013-06-11 | Sterne Agee | Buy | Initiate | |
| 2013-05-31 | Raymond James | Market Perform | Underperform | Downgrade |
| 2013-04-03 | Citigroup | Neutral | Sell | Downgrade |
| 2013-03-27 | Wells Fargo | Outperform | Market Perform | Downgrade |
| 2013-03-18 | Bank of America | Neutral | Initiate | |
| 2013-02-20 | ISI Group | Neutral | Maintains | |
| 2013-02-19 | Jefferies | Hold | Buy | Upgrade |
| 2013-01-14 | Sterne Agee | Buy | Maintains | |
| 2012-12-13 | Wells Fargo | Market Perform | Outperform | Upgrade |
| 2012-12-13 | JP Morgan | Neutral | Overweight | Upgrade |
| 2012-10-31 | Jefferies | Hold | Maintains | |
| 2012-07-10 | ISI Group | Underweight | Initiate | |
| 2012-04-02 | Sterne Agee | Buy | Maintains | |
| 2023-03-28 | Jefferies | Hold | Maintains | |
| 2023-05-15 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2023-05-12 | Wells Fargo | Overweight | Overweight | Maintains |
| 2023-05-12 | Credit Suisse | Outperform | Outperform | Maintains |
| 2024-02-15 | Guggenheim | Buy | Neutral | Downgrade |
| 2023-08-10 | B of A Securities | Buy | Buy | Maintains |
| 2023-11-10 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2023-12-20 | JP Morgan | Overweight | Overweight | Maintains |
| 2024-02-15 | JP Morgan | Overweight | Overweight | Maintains |
| 2023-12-11 | Citigroup | Neutral | Neutral | Maintains |
| 2023-10-24 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2023-09-22 | Guggenheim | Buy | Buy | Maintains |
| 2023-09-22 | Baird | Outperform | Outperform | Maintains |
| 2023-09-22 | Wells Fargo | Overweight | Overweight | Maintains |
| 2023-07-11 | Citigroup | Buy | Neutral | Downgrade |
| 2023-11-09 | UBS | Buy | Buy | Maintains |
| 2023-08-10 | JP Morgan | Overweight | Overweight | Maintains |
| 2023-09-13 | TD Cowen | Market Perform | Initiate | |
| 2024-03-18 | Argus Research | Buy | Buy | Maintains |
| 2023-07-10 | Citigroup | Buy | Neutral | Downgrade |
| 2023-09-25 | TD Cowen | Market Perform | Market Perform | Maintains |
| 2024-05-13 | TD Cowen | Hold | Hold | Maintains |
| 2024-05-10 | Baird | Outperform | Outperform | Maintains |
| 2024-06-07 | Mizuho | Neutral | Initiate | |
| 2024-02-15 | Baird | Outperform | Outperform | Maintains |
| 2024-02-15 | Citigroup | Neutral | Neutral | Maintains |
| 2024-02-15 | UBS | Buy | Buy | Maintains |
| 2024-02-15 | Evercore ISI Group | Outperform | Outperform | Maintains |
| 2024-06-06 | Goldman Sachs | Buy | Initiate | |
| 2024-07-10 | Baird | Outperform | Outperform | Maintains |
| 2024-06-28 | Argus Research | Buy | Hold | Downgrade |
| 2024-06-28 | Barclays | Equal-Weight | Initiate | |
| 2024-10-02 | B of A Securities | Buy | Neutral | Downgrade |
| 2024-10-01 | Citigroup | Neutral | Sell | Downgrade |
| 2024-08-08 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2025-01-23 | Goldman Sachs | Buy | Buy | Maintains |
| 2025-01-14 | William Blair | Outperform | Outperform | Reiterate |
| 2024-09-20 | Baird | Neutral | Neutral | Maintains |
| 2024-10-07 | Evercore ISI Group | Outperform | In-Line | Downgrade |
| 2024-11-07 | Evercore ISI Group | In-Line | In-Line | Maintains |
| 2025-02-05 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2024-12-13 | B of A Securities | Neutral | Neutral | Maintains |
| 2025-02-20 | JP Morgan | Neutral | Neutral | Maintains |
| 2025-02-20 | Baird | Neutral | Neutral | Maintains |
| 2025-02-20 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2024-08-08 | Evercore ISI Group | Outperform | Outperform | Maintains |
| 2024-08-08 | UBS | Buy | Buy | Maintains |
| 2024-08-08 | Goldman Sachs | Buy | Buy | Maintains |
| 2024-08-08 | JP Morgan | Overweight | Neutral | Downgrade |
| 2024-08-08 | Baird | Outperform | Neutral | Downgrade |
| 2024-10-23 | CLSA | Underperform | Initiate | |
| 2025-04-09 | Mizuho | Neutral | Neutral | Maintains |
| 2024-10-14 | Redburn Atlantic | Sell | Initiate | |
| 2024-11-07 | UBS | Buy | Buy | Maintains |
| 2024-08-12 | TD Cowen | Hold | Hold | Maintains |
| 2025-03-04 | Citigroup | Sell | Neutral | Upgrade |
| 2025-01-17 | UBS | Buy | Neutral | Downgrade |
| 2025-03-21 | Goldman Sachs | Buy | Neutral | Downgrade |
| 2025-02-03 | JP Morgan | Neutral | Neutral | Maintains |
| 2025-01-22 | William Blair | Outperform | Market Perform | Downgrade |
| 2024-11-11 | TD Cowen | Hold | Hold | Maintains |
| 2025-07-09 | Evercore ISI Group | Outperform | Outperform | Maintains |
| 2025-07-09 | Citigroup | Neutral | Buy | Upgrade |
| 2025-08-08 | Evercore ISI Group | Outperform | Outperform | Maintains |
| 2025-02-18 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2025-05-23 | Redburn Atlantic | Neutral | Buy | Upgrade |
| 2025-04-10 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2025-08-07 | JP Morgan | Neutral | Neutral | Maintains |
| 2025-08-07 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2025-05-08 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2025-05-08 | Baird | Neutral | Neutral | Maintains |
